Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405059 | 0.85 | PLAT (0.50) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL1138081 | 0.79 | ALDH1A1 (0.46) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL406392 | 0.78 | PLAT (0.46) | PLATALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL24533108 | 0.77 | TSHR (0.46) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL24533114 | 0.76 | PLAT (0.65) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL14881615 | 0.76 | PLAT (0.53) | PLATALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL13522591 | 0.75 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL7101654 | 0.75 | ALDH1A1 (0.46) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL21811179 | 0.75 | PLAT (0.64) | PLATALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL23013790 | 0.74 | PLAT (0.43) | PLATALDH1A1HPGDKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250375451-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | TURNING POINT THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250223298-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-12310968-B2 | Chiral diaryl macrocycles and uses thereof | Turning Point Therapeutics, Inc. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12187739-B2 | Diaryl macrocycle polymorph | Turning Point Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-113354653-B | Diaryl macrocyclic polymorphs and processes for their preparation | 特普医药公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4480543-A2 | CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER | Turning Point Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3733187-B1 | CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER | TURNING POINT THERAPEUTICS INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3856192-B1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-2768509-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2348860-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | PLAT 2221/4885ALDH1A1 855/4885HPGD 4860/4885 |
| US-20250375451-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | PKD1, PKD2, CYP7B1 | PLAT 3873/4885ALDH1A1 2077/4885HPGD 1109/4885 |
| US-12310968-B2 | Chiral diaryl macrocycles and uses thereof | PKD1, DHCR7, PKD2 | PLAT 4236/4885ALDH1A1 3297/4885HPGD 1902/4885 |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PLAT 591/4885ALDH1A1 1236/4885HPGD 2251/4885 |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | ALK, BCR, IDE | PLAT 2913/4885ALDH1A1 377/4885HPGD 4367/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PLAT 591/4885ALDH1A1 1236/4885HPGD 2251/4885 |
| US-12187739-B2 | Diaryl macrocycle polymorph | PKD1, CYP7B1, BRCA1 | PLAT 370/4885ALDH1A1 2198/4885HPGD 177/4885 |
| US-20250223298-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | PLAT 370/4885ALDH1A1 2198/4885HPGD 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.